Fulcrum Therapeutics Inc - FULC Net earnings per one share for the last twelve months

Fulcrum Therapeutics Inc (FULC) - corporate logo

Fulcrum Therapeutics brings together leading geneticists, granting them academic freedom to combat orphan pathologies while delegating drug production to external contractors under an asset-light model. This daily price chart for EPS (TTM), which confirms the market valuation, recorded a value of 11.60. However, financial stability is currently under threat due to regulatory pauses in research, creating a critical imbalance in the pipeline of promising drugs.

FULC: fulcrumtx.com Net earnings per share for the last 12 months 02/11/2024 - 11/18/2026

Fulcrum Therapeutics - analytical breakdowns and key metrics (FULC)

- issuer market value details:
Fundamental company valuation:FULC - Fulcrum Therapeutics Inc
Brand item of Fulcrum Corp

Investors require a fundamental basis for valuing assets within the biotechnology sector. For Fulcrum Therapeutics (FULC), which focuses on developing treatments for muscular dystrophy and anemia, the operating model is characterized by high R&D scientific density. The 12-month annual growth in earnings per share measures net income dynamics over a rolling period, reflecting the impact of monetary factors on margins. The stability of this indicator confirms the financial resilience of Fulcrum Therapeutics (FULC) while awaiting regulatory decisions.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BMRN (BioMarin)|Net earnings per share for the last 12 months BBIO (BridgeBio)|BGM: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Earnings per one share for the last 12 months|Keros Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ARCT (Arcturus Therapeutics)|ETON: Net earnings per share (EPS TTM)|Kamada Ltd (KMDA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)